The burden of moderate to severe psoriasis: An overview

PharmacoEconomics

Volumn 30, Issue 11, 2012, Pages 1005-1013

  Raho, Giovanna ^a   Koleva, Daniela Mihajlova ^b   Garattini, Livio ^b   Naldi, Luigi ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b MARIO NEGRI INST PHARMACOL RES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DATA BASE; DISEASE SEVERITY; HEALTH CARE COST; HUMAN; INFORMATION PROCESSING; PRIORITY JOURNAL; PSORIASIS; QUALITY OF LIFE; REVIEW; SOCIAL BURDEN; SOCIAL STIGMA;

COST OF ILLNESS; HOSPITAL COSTS; HUMANS; PSORIASIS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; STEREOTYPING;

EID: 84867285653     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11591580-000000000-00000     Document Type: Review

References (37)

1. Naldi L. Epidemiology of psoriasis. Curr Drug Targets Inflamm Allergy 2004; 3: 121-8
2. Naldi L, Gambini D. The clinical spectrum of psoriasis. Clinics Dermatol 2007; 25: 510-8
3. Jobling R, Naldi L. Assessing the impact of psoriasis and the relevance of qualitative research. J Invest Dermatol 2006; 126: 1438-40
4. Helliwell PS, Taylor WJ. Classification and diagnostic criteria for psoriatic arthritis. Ann Rheum Dis 2005; 64 Suppl. 2: ii3-8
5. Nijsten T, Wakkee M. Complexities of the association between psoriasis and comorbidities. J Invest Dermatol 2009; 129: 1601-3
6. Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735-41
7. Naldi L, Mercuri SR. Epidemiology of comorbidities in psoriasis. Dermatol Ther 2010; 23: 114-8
8. Nijsten T, Looman CW, Stern RS. Clinical severity of psoriasis in last 20 years of PUVA study. Arch Dermatol 2007; 143: 1113-21
9. Naldi L, Minelli C. Dermatology. In: Machin D, Day S, Green SB, editors. Textbook of clinical trials. 2nd rev. ed. Chichester: John Wiley & Sons, 2007: 261-86
10. Bronsard V, Paul C, Prey S, et al. What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature. J Eur Acad Dermatol Venereol 2010; 24 Suppl. 2: 17-22
11. Jobling R. The experience of psoriasis under treatment. In: Anderson R, Bury M, editors. Living with chronic illness. London: Unwin Hyman, 1988: 225-44
12. EMA Committee for Proprietary Medical Products. Note for guidance on clinical investigation of medical products indicated for the treatment of psoriasis [report no. CPMP/EWP 2454/02]. London: EMA, 2002
13. Naldi L, Griffiths CME. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. Br J Dermatol 2005; 152: 597-615
14. Poulin Y, Langley RG, Teixeira HD, et al. Biologics in the treatment of psoriasis: clinical and economic overview. J Cutan Med Surg 2009; 13 Suppl. 2: S49-57
15. Horn EJ, Fox KM, Patel V, et al. Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey. J Am Acad Dermatol 2007; 57: 957-62
16. Kimball AB, Jacobson C, Weiss S, et al. The psychosocial burden of psoriasis. Am J Clin Dermatol 2005; 6: 383-92
17. Kimball AB, Gieler U, Linder D, et al. Psoriasis: is the impairment to a patient's life cumulative? J Eur Acad Dermatol Venereol 2010; 24 (9): 989-1004
18. Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41 (3 Pt 1): 401-7
19. Richards HL, Fortune DG, Griffiths CE, et al. The contribution of perceptions of stigmatisation to disability in patients with psoriasis. J Psychosom Res 2001; 50: 11-5
20. Davidsson S, Blomqvist K, Molin L, et al. Lifestyle of Nordic people with psoriasis. Int J Dermatol 2005; 44: 378-83
21. Unaeze J, Nijsten T, Murphy A, et al. Impact of psoriasis on health-related quality of life decreases over time: an 11-year prospective study. J Invest Dermatol 2006; 126: 1480-9
22. Gupta MA, Schork N. Suicidal ideation in psoriasis. Int J Dermatol 1993; 32: 188-90
23. Sampogna F, Picardi A, Chren M-M, et al. Association between poorer quality of life and psychiatric morbidity in patients with different dermatological conditions. Psychosom Med 2004; 66: 620-4
24. Langley RGB, Krueger GG, Griffiths CEM. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005; 64 Suppl. II: ii18-23
25. Schmid-Ott G, Schallmayer S, Calliess IT. Quality of life in patients with psoriasis and psoriasis arthritis with a special focus on stigmatization experience. Clin Dermatol 2007; 25: 547-54
26. Schmid-Ott G, Kunsebeck HW, Jager B, et al. Significance of the stigmatization experience of psoriasis patients: a 1-year follow-up of the illness and its psychosocial consequences in men and women. Acta Derm Venereol 2005; 85 (1): 27-32
27. Horn EJ, Fox KM, Patel V, et al. Association of patient-reported psoriasis severity with income and employment. J Am Acad Dermatol 2007; 57: 963-71
28. Eghlileb AM, Davies EEG, Finlay AY. Psoriasis has a major secondary impact on the lives of family members and partners. Br J Dermatol 2007; 156: 1245-50
29. Berger K, Ehlken B, Kugland B, et al. Cost-of-illness in patients with moderate and severe chronic psoriasis vulgaris in Germany. J Dtsch Dermatol Ges 2005; 3: 511-8
30. Carrascosa JM, Pujol R, Dauden E, et al. A prospective evaluation of psoriasis in Spain (EPIDERMA project: phase II). J Eur Acad Dermatol Venereol 2006; 20: 840-5
31. Schœffski O, Augustin M, Prinz J, et al. Costs and quality of life in patients with moderate to severe plaque-type psoriasis in Germany: a multi-center study. J Dtsch Dermatol Ges 2007; 5: 209-18
32. Colombo G, Altomare G, Peris K, et al. Moderate and severe plaque psoriasis: cost-of-illness study in Italy. Ther Clin Risk Manag 2008; 4: 559-68
33. Navarini AA, Laffitte E, Conrad C, et al. Estimation of cost-of-illness in patients with psoriasis in Switzerland. Swiss Med Wkly 2010; 140: 85-91
34. Yu AP, Tang J, Xie J, et al. Economic burden of psoriasis compared to the general population and stratified by disease severity. Curr Med Res Opin, 2009; 25: 2429-38
35. Beyer V, Wolverton ES. Recent trends in systemic psoriasis treatment costs. Arch Dermatol 2010; 146: 46-54
36. European Network of Health Economics Evaluation Databases [online]. Available from URL: http://infodoc.inserm.fr/euronheed [Accessed 2011 Dec 15]
37. Lecluse LL, Naldi L, Stern RS, et al. National registries of systemic treatment for psoriasis and the European 'Psonet' initiative. Dermatology 2009; 218: 347-56